This manuscript outlines a sensible scope for a scoping review of trigeminal neuralgia (TN), covering commonly accepted categories (classical/secondary/idiopathic; TN1 vs TN2), core clinical features and differential diagnosis, and major treatment modalities (carbamazepine/oxcarbazepine; MVD, percutaneous rhizotomy techniques, stereotactic radiosurgery). The structure is coherent and clinically oriented, and the proposed content matches prevailing clinical frameworks, so the high-level conclusion that TN is heterogeneous and requires tailored management would likely be supportable if appropriately sourced. However, as provided it is essentially an annotated outline rather than a completed scoping review: there are no references, no described search strategy, eligibility criteria, study selection process, data charting plan, or synthesis method. Consequently, none of the epidemiology claims (U.S. incidence/prevalence, demographics, underdiagnosis) or comparative statements about outcomes/recurrence can be evaluated, and the review’s conclusions are not justified by presented evidence. To be credible and reproducible as a scoping review, the paper needs a PRISMA-ScR–style methods section, a transparent accounting of included sources, and explicit, cited quantitative estimates (with uncertainty ranges and data provenance) plus a clear separation between evidence-based findings and narrative expert opinion.